Publication date: September 2026 Source: Annals of Thoracic Surgery Short Reports, Volume 4, Issue 3 Author(s): Jonathan D. Spicer, Solange Peters, Justin F. Gainor, Jamie E. Chaft, Christine M. Bestvina, Jay M. Lee, Thomas U. Marron, Muhammad A. Khattak, Laureen S. Ojalvo, Joydeep K. Banerjee, Zheng Wang, Xuan Deng, Nazly Shariati, Steven M. Keller, Tina Cascone
Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer. // Annals of Thoracic Surgery Short Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2772993126001245?dgcid=rss_sd_all
Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer. Annals of Thoracic Surgery Short Reports. https://www.sciencedirect.com/science/article/pii/S2772993126001245?dgcid=rss_sd_all
“Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer.” Annals of Thoracic Surgery Short Reports.
@article{article106778,
title = {Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer},
journal = {Annals of Thoracic Surgery Short Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2772993126001245?dgcid=rss_sd_all}
}